1. Home
  2. ATGL vs ALXO Comparison

ATGL vs ALXO Comparison

Compare ATGL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

N/A

Current Price

$8.90

Market Cap

154.9M

Sector

N/A

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

SELL

Current Price

$1.01

Market Cap

172.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ATGL
ALXO
Founded
2017
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.9M
172.8M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
ATGL
ALXO
Price
$8.90
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $4.60
AVG Volume (30 Days)
102.1K
★ 1.1M
Earning Date
01-27-2027
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.97
$0.86
52 Week High
$50.00
$2.66

Technical Indicators

Market Signals
Indicator
ATGL
ALXO
Relative Strength Index (RSI) 53.51 38.82
Support Level $7.24 $0.86
Resistance Level $11.20 $1.34
Average True Range (ATR) 0.83 0.15
MACD -0.21 -0.01
Stochastic Oscillator 29.46 19.23

Price Performance

Historical Comparison
ATGL
ALXO

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd is a Hong Kong-based AI company. Its business focuses on two main directions: building Exclusive Large Language Model solutions and developing AI Agents. The group specializes in creating Exclusive Large Language Models (LLMs) and bespoke AI platforms. These solutions serve as custom AI brains, enabling enterprises to harness their data for strategic decision-making and operational performance. It guides companies of all sizes through digital transformation with scalable, AI-driven solutions that are ESG-sustainable and designed for long-term growth. The cutting-edge offerings, AlphaClaw AI Agents and the AlphaClaw AI Agent Marketplace to empower organizations across diverse industries to optimize operations, automate workflows, and unlock data-driven insights.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: